Europe Influenza Treatment Market Size & Outlook

The influenza treatment market in Europe is expected to reach a projected revenue of US$ 2,262.1 million by 2030. A compound annual growth rate of 1.3% is expected of Europe influenza treatment market from 2024 to 2030.

Revenue, 2023 (US$M)
$2,073.6
Forecast, 2030 (US$M)
$2,262.1
CAGR, 2024 - 2030
1.3%
Report Coverage
Europe

Europe influenza treatment market highlights

  • The Europe influenza treatment market generated a revenue of USD 2,073.6 million in 2023.
  • The market is expected to grow at a CAGR of 1.3% from 2024 to 2030.
  • In terms of segment, oseltamivir phosphate was the largest revenue generating treatment in 2023.
  • Baloxavir Marboxil is the most lucrative treatment segment registering the fastest growth during the forecast period.
  • Country-wise, UK is expected to register the highest CAGR from 2024 to 2030.

Europe data book summary

Market revenue in 2023USD 2,073.6 million
Market revenue in 2030USD 2,262.1 million
Growth rate1.3% (CAGR from 2023 to 2030)
Largest segmentOseltamivir phosphate
Fastest growing segmentBaloxavir Marboxil
Historical data covered2018 - 2022
Base year for estimation2023
Forecast period covered2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationPeramivira, Zanamivir, Baloxavir Marboxil, Oseltamivir Phosphate
Key market players worldwideNovartis AG ADR, Roche Holding AG, BioCryst Pharmaceuticals Inc, Sanofi SA, GSK PLC, GSK PLC ADR, Viatris Inc, Teva Pharmaceutical Industries Ltd, Daiichi Sankyo Co Ltd, AstraZeneca PLC

Other key industry trends

  • In terms of revenue, Europe region accounted for 35.1% of the global influenza treatment market in 2023.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2030.
  • Asia Pacific is the fastest growing regional market and is projected to reach USD 795.5 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Influenza Treatment Market Companies

Name Profile # Employees HQ Website

Europe influenza treatment market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to influenza treatment market will help companies and investors design strategic landscapes.


Oseltamivir phosphate was the largest segment with a revenue share of 27.6% in 2023. Horizon Databook has segmented the Europe influenza treatment market based on peramivira, zanamivir, baloxavir marboxil, oseltamivir phosphate covering the revenue growth of each sub-segment from 2018 to 2030.


  • Europe Influenza Treatment Treatment Outlook (Revenue, USD Million, 2018-2030)
    • Peramivira
    • Zanamivir
    • Baloxavir Marboxil
    • Oseltamivir Phosphate
    • Others
  • Europe Influenza Treatment Route of Administration Outlook (Revenue, USD Million, 2018-2030)
    • Oral
    • Others
  • Europe Influenza Treatment Distribution Channel Outlook (Revenue, USD Million, 2018-2030)
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy

Reasons to subscribe to Europe influenza treatment market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Europe influenza treatment market databook

  • Our clientele includes a mix of influenza treatment market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the Europe influenza treatment market , including forecasts for subscribers. This continent databook contains high-level insights into Europe influenza treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Europe influenza treatment market size, by country, 2018-2030 (US$M)

Europe Influenza Treatment Market Outlook Share, 2023 & 2030 (US$M)

Europe influenza treatment market size, by country, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more